Cargando…

A Narrative Review on Axonal Neuroprotection in Multiple Sclerosis

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) resulting in demyelination and neurodegeneration. The therapeutic strategy is now largely based on reducing inflammation with immunosuppressive drugs. Unfortunately, when disease progression is observed, no...

Descripción completa

Detalles Bibliográficos
Autores principales: Collongues, Nicolas, Becker, Guillaume, Jolivel, Valérie, Ayme-Dietrich, Estelle, de Seze, Jérôme, Binamé, Fabien, Patte-Mensah, Christine, Monassier, Laurent, Mensah-Nyagan, Ayikoé Guy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338208/
https://www.ncbi.nlm.nih.gov/pubmed/35610531
http://dx.doi.org/10.1007/s40120-022-00363-7
_version_ 1784759918191968256
author Collongues, Nicolas
Becker, Guillaume
Jolivel, Valérie
Ayme-Dietrich, Estelle
de Seze, Jérôme
Binamé, Fabien
Patte-Mensah, Christine
Monassier, Laurent
Mensah-Nyagan, Ayikoé Guy
author_facet Collongues, Nicolas
Becker, Guillaume
Jolivel, Valérie
Ayme-Dietrich, Estelle
de Seze, Jérôme
Binamé, Fabien
Patte-Mensah, Christine
Monassier, Laurent
Mensah-Nyagan, Ayikoé Guy
author_sort Collongues, Nicolas
collection PubMed
description Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) resulting in demyelination and neurodegeneration. The therapeutic strategy is now largely based on reducing inflammation with immunosuppressive drugs. Unfortunately, when disease progression is observed, no drug offers neuroprotection apart from its anti-inflammatory effect. In this review, we explore current knowledge on the assessment of neurodegeneration in MS and look at putative targets that might prove useful in protecting the axon from degeneration. Among them, Bruton’s tyrosine kinase inhibitors, anti-apoptotic and antioxidant agents, sex hormones, statins, channel blockers, growth factors, and molecules preventing glutamate excitotoxicity have already been studied. Some of them have reached phase III clinical trials and carry a great message of hope for our patients with MS.
format Online
Article
Text
id pubmed-9338208
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-93382082022-07-31 A Narrative Review on Axonal Neuroprotection in Multiple Sclerosis Collongues, Nicolas Becker, Guillaume Jolivel, Valérie Ayme-Dietrich, Estelle de Seze, Jérôme Binamé, Fabien Patte-Mensah, Christine Monassier, Laurent Mensah-Nyagan, Ayikoé Guy Neurol Ther Review Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) resulting in demyelination and neurodegeneration. The therapeutic strategy is now largely based on reducing inflammation with immunosuppressive drugs. Unfortunately, when disease progression is observed, no drug offers neuroprotection apart from its anti-inflammatory effect. In this review, we explore current knowledge on the assessment of neurodegeneration in MS and look at putative targets that might prove useful in protecting the axon from degeneration. Among them, Bruton’s tyrosine kinase inhibitors, anti-apoptotic and antioxidant agents, sex hormones, statins, channel blockers, growth factors, and molecules preventing glutamate excitotoxicity have already been studied. Some of them have reached phase III clinical trials and carry a great message of hope for our patients with MS. Springer Healthcare 2022-05-24 /pmc/articles/PMC9338208/ /pubmed/35610531 http://dx.doi.org/10.1007/s40120-022-00363-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Review
Collongues, Nicolas
Becker, Guillaume
Jolivel, Valérie
Ayme-Dietrich, Estelle
de Seze, Jérôme
Binamé, Fabien
Patte-Mensah, Christine
Monassier, Laurent
Mensah-Nyagan, Ayikoé Guy
A Narrative Review on Axonal Neuroprotection in Multiple Sclerosis
title A Narrative Review on Axonal Neuroprotection in Multiple Sclerosis
title_full A Narrative Review on Axonal Neuroprotection in Multiple Sclerosis
title_fullStr A Narrative Review on Axonal Neuroprotection in Multiple Sclerosis
title_full_unstemmed A Narrative Review on Axonal Neuroprotection in Multiple Sclerosis
title_short A Narrative Review on Axonal Neuroprotection in Multiple Sclerosis
title_sort narrative review on axonal neuroprotection in multiple sclerosis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338208/
https://www.ncbi.nlm.nih.gov/pubmed/35610531
http://dx.doi.org/10.1007/s40120-022-00363-7
work_keys_str_mv AT collonguesnicolas anarrativereviewonaxonalneuroprotectioninmultiplesclerosis
AT beckerguillaume anarrativereviewonaxonalneuroprotectioninmultiplesclerosis
AT jolivelvalerie anarrativereviewonaxonalneuroprotectioninmultiplesclerosis
AT aymedietrichestelle anarrativereviewonaxonalneuroprotectioninmultiplesclerosis
AT desezejerome anarrativereviewonaxonalneuroprotectioninmultiplesclerosis
AT binamefabien anarrativereviewonaxonalneuroprotectioninmultiplesclerosis
AT pattemensahchristine anarrativereviewonaxonalneuroprotectioninmultiplesclerosis
AT monassierlaurent anarrativereviewonaxonalneuroprotectioninmultiplesclerosis
AT mensahnyaganayikoeguy anarrativereviewonaxonalneuroprotectioninmultiplesclerosis
AT collonguesnicolas narrativereviewonaxonalneuroprotectioninmultiplesclerosis
AT beckerguillaume narrativereviewonaxonalneuroprotectioninmultiplesclerosis
AT jolivelvalerie narrativereviewonaxonalneuroprotectioninmultiplesclerosis
AT aymedietrichestelle narrativereviewonaxonalneuroprotectioninmultiplesclerosis
AT desezejerome narrativereviewonaxonalneuroprotectioninmultiplesclerosis
AT binamefabien narrativereviewonaxonalneuroprotectioninmultiplesclerosis
AT pattemensahchristine narrativereviewonaxonalneuroprotectioninmultiplesclerosis
AT monassierlaurent narrativereviewonaxonalneuroprotectioninmultiplesclerosis
AT mensahnyaganayikoeguy narrativereviewonaxonalneuroprotectioninmultiplesclerosis